2021 Annual Global Meeting: Virtual-Plenary V: Oral Abstract Presentations

Video Transcription

Video Summary

Thank you for joining us for this session. Here is a summary of the key points discussed. In the first presentation, Dr. Brad Monk shared the results of a phase 1b study evaluating tizodimab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer. The study found that the combinations were well tolerated with no dose-limiting toxicities observed. The recommended phase 2 dose was determined to be the full dose of tizodimab vedotin in combination with each of the three agents. Preliminary efficacy data showed promising response rates, with the combination of tizodimab vedotin and bevacizumab demonstrating a 20.7% response rate in PD-L1 negative patients. In the second presentation, Dr. Han discussed a phase 1 study evaluating the safety and preliminary efficacy of PD-L1 antibody, so-casolamab, in recurrent or metastatic cervical cancer. The study enrolled 94 patients and found an overall response rate of 18.1% and a median progression-free survival of 4.5 months. Notably, the study showed that so-casolamab had good safety and efficacy in patients with metastatic or recurrent cervical cancer, regardless of PD-L1 status. The results suggest that so-casolamab could be a promising treatment option for these patients. In summary, both studies demonstrate the potential of immunotherapies in the treatment of cervical cancer, with promising response rates and manageable side effects. These findings highlight the evolving landscape of cervical cancer therapy and the importance of further research in this area.

Keywords

Dr. Brad Monk

tizodimab vedotin

bevacizumab

pembrolizumab

carboplatin

recurrent cervical cancer

metastatic cervical cancer

response rates

PD-L1 negative patients

so-casolamab